Genmab — Juli 2018

[Helge_LarsenPI-redaktør]

Månedsgrafen ser flot og sund ud. Der er ikke mange flade etaper undervejs.

[bibob]

Tak Helge. Lad os håbe det holder.

[E_L]

Nivolumab (opdivo) with Dara trial updated https://clinicaltrials.gov/ct2/history/NCT03098550?A=19&B=20&C=merged

[polle1]

Helge : mobile pay'ed donation, tusind tak for et super site !!

[E_L]

Trial of Dara in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL) was withdrawn, it was supposed to start this month
https://clinicaltrials.gov/ct2/history/NCT03207542?A=6&B=7&C=merged

[E_L]

nobody was ever recruited it seems

[Helge_LarsenPI-redaktør]

Danske købere er på ferie. Næst største køber efter A/B er svenske Avanza med hele 3 stk. aktier.

[Helge_LarsenPI-redaktør]

Altså netto efter køb af 10 stk og salg af 7.

[Helge_LarsenPI-redaktør]

Ligner et fornuftigt luk. Det mener Avanza også - og har derfor købt et stk. ekstra aktie.

[Helge_LarsenPI-redaktør]

[E_L]

Kinase inhibitor advances in MM: predictive biomarkers & efficacy of daratumumab http://www.oncologytube.com/video/kinase-inhibitor-advances-in-mm-predictive-biomarkers-efficacy-of-daratumumab/10004733

[bibob]

Er der ikke CMPH møde 23 - 26 juli. ? Og er der noget nyt om Dara !!

[Raffles]

Jeg har ikke set noget nyt fra CMPH-mødet. Meeting highlights fra møder 25-28/6 kom d. 29/6, så vi kan håbe der kommer tilsvarende highlights i morgen.

[bibob]

Ok tak.

[hda]

Friday after Committee plenary

[hda]

http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/document_listing/document_listing_000378.jsp&mid=WC0b01ac0580028d2a

[E_L]

Trial represents ‘bold move’ for treatment of newly diagnosed myeloma - https://www.healio.com/hematology-oncology/myeloma/news/online/{1ebabaf8-6883-4567-8253-bc4ce2e72ecf}/trial-represents-bold-move-for-treatment-of-newly-diagnosed-myeloma

[E_L]

from Seattle Genetics Q2 2018 Results http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=RssLanding&cat=news&id=2360357

[E_L]

Tisotumab Vedotin (TV) Program Activities
• Metastatic Cervical Cancer Trial Initiated: Seattle Genetics and Genmab initiated a phase 2 trial called innovaTV 204 in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment. The trial will enroll approximately 100 patients and is intended to potentially support registration under the FDA's accelerated approval pathway.

[E_L]

• Solid Tumor Trial Initiated: Seattle Genetics and Genmab initiated a phase 2 clinical trial called innovaTV 207 in several types of solid tumors. The trial is intended to inform a potential broad development program.